On this page
KCNQ1
potassium voltage-gated channel subfamily Q member 1
The KCNQ1 gene provides instructions for making a protein that forms a critical part of voltage-gated potassium channels, which are essential for regulating electrical signals in the heart and inner ear. KCNQ1 is a gene central to the proper function of potassium channels, particularly in cardiac muscle and the inner ear.
KCNQ1 is located on the short (p) arm of chromosome 11, at band 11p15.5-p15.4. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 11 in the library →Overview
The KCNQ1 gene, also known as potassium voltage-gated channel subfamily Q member 1, is a crucial component of the genetic machinery responsible for forming potassium channels. These channels are integral membrane proteins that facilitate the movement of positively charged potassium ions across cell membranes [PMID:24151703]. This ion transport is fundamental for generating and transmitting electrical signals within various tissues throughout the body.
KCNQ1-encoded channels are primarily found in the heart and the inner ear, where they have distinct physiological roles. In the heart, they are involved in the repolarisation phase of the cardiac action potential, ensuring a regular heart rhythm. In the inner ear, these channels contribute to maintaining the precise ion balance necessary for auditory function [PMID:17951235]. Dysregulation of KCNQ1 function due to genetic variants can lead to a range of conditions, predominantly impacting cardiac electrical stability.
What the gene does
The KCNQ1 gene encodes an alpha subunit of a voltage-gated potassium channel, which is a protein that allows potassium ions to flow out of cells in response to changes in membrane potential. These channels are crucial for the electrical excitability of cells and the regulation of cellular processes that depend on ion gradients. The specific function of a potassium channel formed by KCNQ1 depends on its cellular location and the other proteins it interacts with.
In cardiac muscle cells, KCNQ1 proteins assemble into channels that are critical for the repolarisation phase of the action potential. This repolarisation, often referred to as the 'recharging' of the cardiac muscle, is essential for maintaining a regular heart rhythm. When the heart's electrical signals are disrupted, it can lead to arrhythmias. The KCNQ1 protein commonly interacts with proteins from the KCNE family, such as KCNE1, to form a functional channel complex. Four KCNQ1 alpha subunits typically form the central pore of the channel, while a KCNE beta subunit binds to this complex, regulating its activity and kinetic properties [PMID:17951235].
Beyond the heart, KCNQ1 channels are also highly expressed in the inner ear. Here, they contribute to the maintenance of the endolymphatic potential, which is vital for the normal functioning of auditory hair cells and thus for hearing [PMID:24151703]. The KCNQ1 protein is also found in other organs including the kidney, lung, stomach, and intestine, suggesting broader roles in ion homeostasis and fluid secretion across different physiological systems. The precise composition and regulation of these channels can vary depending on the tissue, highlighting the versatility of KCNQ1 in ion channel physiology.
Video: Genetics 101
Chromosome location
The KCNQ1 gene is located on the short arm of chromosome 11, specifically within the region designated 11p15.5-p15.4. This chromosomal region is known to harbour various genes important for normal physiological function. The human genome contains 23 pairs of chromosomes, and chromosome 11 is one of the larger autosomes. The precise location of KCNQ1 means that genetic variations in this area can have specific consequences, particularly relating to the cardiac and auditory systems.
Protein structure
The KCNQ1 protein, which has a length of 676 amino acids, is a complex transmembrane protein structured to form an ion channel. Its architecture includes several distinct functional and structural domains. At the N-terminus, there are two separate disordered regions, located at amino acids 1-28 and 62-84, which likely contribute to the protein's flexibility and potential for diverse interactions.
Within the cytoplasmic regions, several interaction domains have been identified. An important interaction site for KCNE3, a regulatory subunit, is located between amino acids 238-246. Further into the protein, two distinct regions interact with Calmodulin (CALM): one at amino acids 370-382 and another, calcium-dependent interaction site, at amino acids 515-529. These CALM interactions are crucial for calcium-dependent regulation of channel activity.
The C-terminus of KCNQ1 contains a region spanning amino acids 535-572 that specifically interacts with the C-terminus of KCNE1, another vital regulatory subunit. Towards the very end of the protein, a coiled-coil domain, from amino acids 585-621, is present. This region overlaps with an interaction site for AKAP9 (amino acids 588-616) and a C-terminal assembly domain (amino acids 589-620), which is essential for the tetramerization of four KCNQ1 subunits into a functional channel. The very C-terminal end, from amino acids 620-676, is another disordered region, which may also be involved in regulatory interactions.
Key variants
Variants in the KCNQ1 gene can significantly impact the function of the potassium channels it encodes, leading to a range of health conditions. These genetic changes can vary widely, including single nucleotide changes (missense variants), small insertions or deletions, and larger rearrangements. The precise effect of a variant depends on its location within the gene and how it alters the KCNQ1 protein's structure or function. Some variants may lead to a loss of channel function, while others might cause a gain of function or altered regulation. The clinical presentation of these variants can be highly variable, even within the same condition, influenced by factors such as the specific variant, other genetic modifiers, and environmental influences.
Sample of pathogenic variants
10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.
| Variant (HGVS) | Protein change | Classification | Evidence | Associated condition |
|---|---|---|---|---|
c.1032G>A | p.Ala344= | Pathogenic | ★★★☆ | Long QT syndrome 1 |
c.1766G>A | p.Gly589Asp | Pathogenic | ★★★☆ | Long QT syndrome 1 |
c.760G>A | p.Val254Met | Pathogenic | ★★★☆ | Long QT syndrome 1 |
c.1008del | p.Ile337fs | Pathogenic | ★★☆☆ | not provided |
c.102C>A | p.Cys34Ter | Pathogenic/Likely pathogenic | ★★☆☆ | Congenital long QT syndrome |
c.1038del | p.Gly348fs | Pathogenic/Likely pathogenic | ★★☆☆ | Long QT syndrome |
c.107dup | p.Ser37fs | Pathogenic | ★★☆☆ | Long QT syndrome |
c.1095_1096delinsAT | p.Asn365_Arg366delinsLysTrp | Pathogenic/Likely pathogenic | ★★☆☆ | Cardiovascular phenotype |
c.1129-4_1151del | - | Pathogenic/Likely pathogenic | ★★☆☆ | Long QT syndrome |
c.1393+1G>A | - | Pathogenic/Likely pathogenic | ★★☆☆ | KCNQ1-related disorder |
Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.
Associated conditions
Variants in the KCNQ1 gene are associated with several inherited conditions, primarily affecting cardiac electrical activity and, in some cases, hearing. These include different forms of Long QT syndrome, Short QT syndrome, and familial atrial fibrillation. The inheritance pattern can vary depending on the specific condition and variant type. For example, Long QT syndrome type 1 is typically inherited in an autosomal dominant manner, while Jervell and Lange-Nielsen syndrome, which combines profound hearing loss with cardiac issues, follows an autosomal recessive inheritance pattern. Long QT syndrome can also present with a digenic inheritance pattern, implying involvement of variants in more than one gene.
Inheritance pattern
Conditions caused by pathogenic KCNQ1 variants typically follow autosomal dominant inheritance.
Each child has a 50% chance of inheriting the pathogenic variant, regardless of sex.
UK clinical status
In the UK, the KCNQ1 gene is recognised on several NHS Genomic Medicine Service national panels, highlighting its clinical significance. It is classified as 'green' on the DDG2P panel, indicating strong evidence for gene-disease association. KCNQ1 is also listed as 'green' on panels for Long QT syndrome (R127) and Short QT syndrome (R130), reflecting its well-established role in these cardiac arrhythmias. Furthermore, the gene is included on the Monogenic hearing loss panel (R67) and the Pituitary hormone deficiency panel (R159), showing its association with a broader range of conditions and thus clinical utility in these areas.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Diet & lifestyle considerations
Research suggests that certain lifestyle factors may influence the severity or management of conditions associated with KCNQ1 variants, particularly those affecting cardiac rhythm. For individuals with inherited arrhythmias like Long QT syndrome, avoiding certain medications known to prolong the QT interval is generally recommended [PMID:24151703]. Regular, moderate physical activity, tailored to individual circumstances and under medical guidance, is often encouraged for general cardiovascular health. However, individuals with certain cardiac channelopathies may need to avoid intense or competitive sports due to the risk of arrhythmias, and they should consult with their healthcare provider for personalised advice. Maintaining a balanced diet rich in fruits, vegetables, and whole grains supports overall heart health. Limiting caffeine and alcohol intake may also be beneficial for some individuals with cardiac rhythm disturbances. these are general population observations, and any lifestyle changes should always be discussed with a doctor, especially for individuals with a diagnosed genetic condition.
Supplement considerations
Currently, there is no conclusive scientific evidence to suggest that specific dietary supplements can prevent or cure conditions associated with KCNQ1 variants. For some individuals with Long QT syndrome, maintaining adequate levels of electrolytes such as potassium and magnesium is important, as imbalances can exacerbate cardiac rhythm issues [PMID:24151703]. However, this is typically managed through diet and, if necessary, prescribed medication, rather than over-the-counter supplements, unless specifically advised by a healthcare professional. Any consideration of supplement use, including vitamins, minerals, or herbal remedies, should be thoroughly discussed with a doctor or a qualified dietitian. This is particularly important because certain supplements can interact with medications or have their own cardiac effects, which could be detrimental for individuals with underlying heart conditions.
Frequently asked questions
What is the primary function of the KCNQ1 gene?
The KCNQ1 gene provides instructions for making a protein that forms a key component of voltage-gated potassium channels. These channels are crucial for the flow of potassium ions across cell membranes, which is essential for generating and transmitting electrical signals, particularly in the heart for rhythm regulation and in the inner ear for hearing.
Which conditions are commonly associated with KCNQ1 variants?
Variants in KCNQ1 are primarily associated with inherited cardiac conditions such as Long QT syndrome (type 1 and digenic forms), Short QT syndrome, and familial atrial fibrillation. It is also a major cause of Jervell and Lange-Nielsen syndrome, which involves both profound hearing loss and cardiac rhythm disturbances.
How do KCNQ1 variants cause disease?
KCNQ1 variants can disrupt the normal function of the potassium channels. This disruption might lead to either a reduced (loss-of-function) or increased (gain-of-function) flow of potassium ions, altering the electrical signalling in affected cells. For example, in the heart, this can lead to an unstable electrical rhythm.
What is the inheritance pattern for KCNQ1-related conditions?
The inheritance pattern varies. Long QT syndrome type 1 is typically autosomal dominant, meaning one altered copy of the gene is sufficient to cause the condition. Jervell and Lange-Nielsen syndrome is autosomal recessive, requiring two altered copies. Some forms of Long QT syndrome can also be digenic.
Is KCNQ1 relevant for hearing?
Yes, KCNQ1 is highly relevant for hearing. In the inner ear, the channels formed by the KCNQ1 protein help maintain the proper ion balance necessary for the function of auditory hair cells. Variants in KCNQ1 are a significant cause of monogenic hearing loss, especially in Jervell and Lange-Nielsen syndrome.
Are there specific lifestyle recommendations for individuals with KCNQ1 variants?
For individuals with KCNQ1-associated cardiac conditions, general recommendations often include avoiding certain medications that can affect heart rhythm and discussing exercise levels with a healthcare provider. Maintaining a balanced diet and managing electrolytes are also important. All lifestyle adjustments should be made in consultation with a medical professional.
References
- Ioakeimidis NS, Papamitsou T, Meditskou S. Sudden infant death syndrome due to long QT syndrome: a brief review of the genetic substrate and prevalence. Journal of biological research (Thessalonike, Greece). 2017. PMID: 28316956
- Chan PJ, Osteen JD, Xiong D. Characterization of KCNQ1 atrial fibrillation mutations reveals distinct dependence on KCNE1. The Journal of general physiology. 2012. PMID: 22250012
- Arnestad M, Crotti L, Rognum TO. Prevalence of long-QT syndrome gene variants in sudden infant death syndrome. Circulation. 2007. PMID: 17210839
- Park KH, Piron J, Dahimene S. Impaired KCNQ1-KCNE1 and phosphatidylinositol-4,5-bisphosphate interaction underlies the long QT syndrome. Circulation research. 2005. PMID: 15746441
- Hong K, Piper DR, Diaz-Valdecantos A. De novo KCNQ1 mutation responsible for atrial fibrillation and short QT syndrome in utero. Cardiovascular research. 2005. PMID: 16109388
- Jespersen T, Grunnet M, Olesen SP. The KCNQ1 potassium channel: from gene to physiological function. Physiology (Bethesda, Md.). 2005. PMID: 16287990
- Paulussen AD, Gilissen RA, Armstrong M. Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. Journal of molecular medicine (Berlin, Germany). 2004. PMID: 14760488
- Bellocq C, van Ginneken AC, Bezzina CR. Mutation in the KCNQ1 gene leading to the short QT-interval syndrome. Circulation. 2004. PMID: 15159330
- Melman YF, Um SY, Krumerman A. KCNE1 binds to the KCNQ1 pore to regulate potassium channel activity. Neuron. 2004. PMID: 15207237
- Ellinor PT, Moore RK, Patton KK. Mutations in the long QT gene, KCNQ1, are an uncommon cause of atrial fibrillation. Heart (British Cardiac Society). 2004. PMID: 15547041
- Tristani-Firouzi M, Sanguinetti MC. Structural determinants and biophysical properties of HERG and KCNQ1 channel gating. Journal of molecular and cellular cardiology. 2003. PMID: 12623297
- Wang Z, Li H, Moss AJ. Compound heterozygous mutations in KvLQT1 cause Jervell and Lange-Nielsen syndrome. Molecular genetics and metabolism. 2002. PMID: 12051962
- Herbert E, Trusz-Gluza M, Moric E. KCNQ1 gene mutations and the respective genotype-phenotype correlations in the long QT syndrome. Medical science monitor : international medical journal of experimental and clinical research. 2002. PMID: 12388934
- Huang L, Bitner-Glindzicz M, Tranebjaerg L. A spectrum of functional effects for disease causing mutations in the Jervell and Lange-Nielsen syndrome. Cardiovascular research. 2001. PMID: 11530100
- Adam MP, Bick S, Mirzaa GM. Long QT Syndrome Overview. 1993. PMID: 20301308
- Adam MP, Bick S, Mirzaa GM. Jervell and Lange-Nielsen Syndrome. 1993. PMID: 20301579